Espervita Therapeutics develops metabolic reprogramming therapies targeting cancers with significant unmet medical need, starting with liver cancer. Their preclinical work shows these novel therapies inhibit cancer cell proliferation and reduce tumor burden. The company focuses on creating effective systemic therapeutics where current treatment options offer limited survival improvement.
Funding
Funding not disclosed
Founders
Product
Problem
Liver cancer is a rapidly growing cancer in North America and a leading cause of cancer-related deaths globally, yet current systemic therapies offer limited survival improvements. This creates a significant unmet medical need for effective treatments.
Solution
Espervita Therapeutics is developing metabolic reprogramming therapies designed to treat cancers with high unmet needs, starting with liver cancer. Their approach targets the altered metabolism of cancer cells, inhibiting proliferation and enhancing immune detection. Preclinical models demonstrate that these therapies can reduce tumor burden.
Target Audience
The primary target audience includes cancer patients, particularly those with liver cancer, and the medical community seeking more effective systemic therapies.
Features
- Metabolic reprogramming approach to disrupt cancer cell proliferation.
- Therapies designed to increase immune detection of cancer cells.
- Preclinical evidence showing reduction in tumor burden.